Difference between revisions of "Escitalopram-mianserine"

From Psychiatrienet
Jump to: navigation, search
 
Line 5: Line 5:
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start mianserine in a low dosage of 30 mg/day.
 
* '''Day 1:''' simultaneously start mianserine in a low dosage of 30 mg/day.
* '''Day 8:''' stop administration of escitalopram and continue administration of mianserine.
+
* '''Day 8:''' continue administration of mianserine.
 
| info =  
 
| info =  
 
}}
 
}}

Latest revision as of 15:04, 5 March 2010

Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine

Switch medication from escitalopram to mianserine.[1] [2]

Nietinrijdenbord.png Stop escitalopram
  • Before day 1: gradually reduce dosage of escitalopram to a maximum of 10 mg/day, when this dosage is >10 mg/day.
  • Day 1: reduce dosage of escitalopram to a maximum of 5 mg/day.
  • Day 8: stop administration of escitalopram.
Eenrichtingbord.png Start mianserine
  • Day 1: simultaneously start mianserine in a low dosage of 30 mg/day.
  • Day 8: continue administration of mianserine.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.